Low testosterone tracks with diabetes. Replacing it helps a little, at a cost

Low testosterone in men travels with obesity, metabolic syndrome and type 2 diabetes — but the arrow points mostly from the excess fat to the low hormone, not the other way, and testosterone is not a treatment for the metabolic disease itself [s1][s3]. The one large trial that tested whether testosterone can prevent diabetes found a real but modest effect, bought with measurable safety trade-offs [s1].

An association, and which way it runs

That men who are overweight or obese frequently have low serum testosterone, and that low testosterone is in turn associated with a higher risk of type 2 diabetes, is well established [s1]. The clinically important point is causal direction. Much of the low testosterone seen in men with big waists is a consequence of adiposity and metabolic ill-health rather than its cause, which is why the tempting shortcut — top up the hormone and fix the metabolism — has to be tested directly rather than assumed.

The trial that tested it

That test is T4DM, a two-year randomised, double-blind, placebo-controlled trial at six Australian centres. It enrolled 1,007 men aged 50 to 74 with a waist circumference of 95 cm or more, a serum testosterone of 14.0 nmol/L or lower but no pathological cause of hypogonadism, and either impaired glucose tolerance or newly diagnosed type 2 diabetes [s1]. Every participant entered a community-based lifestyle programme, then was randomised to intramuscular testosterone undecanoate (1,000 mg) or placebo, dosed at baseline, six weeks, and every three months thereafter [s1].

At two years, type 2 diabetes — a 2-hour glucose of 11.1 mmol/L or higher on an oral glucose tolerance test — was present in 87 of 413 men (21%) in the placebo group and 55 of 443 (12%) in the testosterone group, a relative risk of 0.59 (95% CI 0.43 to 0.80) [s1]. Mean 2-hour glucose fell by 0.95 mmol/L on placebo and by 1.70 mmol/L on testosterone [s1]. That is a genuine reduction in a hard-ish endpoint, and it is why the trial drew attention.

Two caveats sit inside the same paper. First, testosterone was an add-on: every man was already in a lifestyle programme, so the drug did not replace losing weight, it was layered on top of that effort [s1]. Second, the treatment moved a safety marker — the trial's authors singled out increases in haematocrit, the thickness of the blood, as potentially treatment-limiting, and noted that longer-term durability, safety and cardiovascular effects remained to be investigated [s1].

What the cardiovascular data later showed

Some of that missing safety evidence arrived with TRAVERSE, designed to answer whether testosterone is safe for the heart. It randomised 5,246 men aged 45 to 80 who had symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and either established cardiovascular disease or a high risk of it, to transdermal testosterone gel or placebo [s2]. Over a mean follow-up of 33.0 months, a first cardiovascular event — cardiovascular death, non-fatal heart attack or non-fatal stroke — occurred in 182 men (7.0%) on testosterone and 190 (7.3%) on placebo, a hazard ratio of 0.96 (95% CI 0.78 to 1.17) that met the pre-set bar for non-inferiority [s2]. Reassuring on the headline endpoint — but the trial also recorded a higher incidence of atrial fibrillation among men taking testosterone [s2]. Cardiac neutrality is not the same as being risk-free.

Where guidelines draw the line

The Endocrine Society's 2018 clinical practice guideline is deliberately restrictive about who should be diagnosed and treated at all. It recommends making a diagnosis of hypogonadism only in men who have both symptoms and signs of testosterone deficiency and unequivocally, consistently low serum testosterone, measured as fasting morning total testosterone on a reliable assay and confirmed on a repeat test [s3]. That standard is a check against treating a low number in isolation: a man whose only problem is a metabolic risk profile does not meet it [s3].

What it means for a reader

The honest summary is unglamorous. Low testosterone in men is often a marker of the same excess weight and metabolic disease that drives type 2 diabetes; testosterone therapy can modestly reduce progression to diabetes on top of a lifestyle programme, but it is not a substitute for weight loss and it nudges haematocrit up and makes atrial fibrillation more common [s1][s2]. Guidelines still reserve it for men with genuine symptoms and confirmed deficiency, not for metabolic risk on its own [s3].

That places the metabolic case for testosterone well behind the reasons it is more conventionally prescribed — the workup of true deficiency (causes of male hypogonadism), persistent low libido and sexual symptoms, and the separate, unresolved question of its prostate-cancer risk. It is also worth remembering that some low readings have ordinary, reversible drivers, including poor sleep, before any prescription is written.